FDA Clears Way for Boosters Targeting Latest Covid Variants (2)

Aug. 31, 2022, 5:17 PM UTC

Covid-19 boosters from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE that are tailored to the latest omicron variants got US regulatory clearance, a move toward additional protection as concern grows about potential new waves in the fall and winter.

The emergency use authorization is for use of a dose of Moderna’s shot in adults 18 and older, while Pfizer’s can be used in people 12 and older, the Food and Drug Administration said Tuesday in a statement. The booster must be given at least two months after recipients’ latest Covid shot. Advisers to the US ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.